Myrcludex B Trial Update?

[Mrt79]

Hi Guys,
Anyone with update about Myrcludex B trial please update the community.
OCT has been awarded the trial but not much has been heard about the progress.
http://out-clinicaltrials.com/?q=content/oct-starts-phase-2a-multinational-clinical-trial-hepatitis-b-virus-infection

[clarkolofsson]

HIV is not solved. Bone marrow transplantation (HSCT) is far too dangerous to be a treatment to cure HIV. It´s also impossible to find matching donors with correct receptors for all HIV-infected people. In fact HSCT might not be possible at all in a few years due to emeringing resistance problems among bacterias.

Regarding HBV we have the possibility already today to almost eradicate it within a few generations by preventing mother-to-child-tramsmission (PMTCT) and make sure that every child born gets vaccinated. In Sweden we estimate the cost for vaccination to be around $ 1 million/years to immunize to whole cohort born. If we have 0,1% of every child born on earth that would make around $ 1 billion/year to immunize every child in the world.

Compare that to what we gave the banks when they stole our money...

[R_2012]

Did not mean it as discouragement regarding any of these drugs.  I was merely implying that they are on the same schedule at this point.  We all would like the process to go faster so hopefully some will move along faster.  Competition is great and the first to finish line will be rewarded handsomely.  Next year should be full of updates on these candidates.    

From the current schedules, it appears that 2017 would be the year that some of these might make it to market.  Coincidence that Tenofovir goes off patent that year?  I'm not that cynical but it can be construed as tinfoil-hat time. (-:  I for one I'm glad these companies continue to invest on finding cures for HBV.      

[StephenCastlecrag]

Yeah, I know what alcohol and how you use it too!  LOL.

[andrey19]

Maybe Replicor and GS-9620 drugs are ahead but it seems having positive results on papers is a very opposite thing from being even close to be  available on the market. How long do they have these results available inside the company? Anybody knows for sure? Replicor/Gilead/Hepatera are all competitors willing to get biggest hbv market share. The bigger number of real competitors we have, the more chance something good happen! I think coming news like that from each other will push them to move forward quicker rather then be sure no other company is doing anything for new drug development, so they can simply enjoy cashflow and wait for their patent to get expired and then come with a new drug right at that date. Another thing I am sure that Myrcludex gives more benefits to hbvers rather than Baraclude or Viread otherwise developing Myrcludex doesn't make any sence and frankly I do not care if I have to take Myrcludex together with other drugs if this is a way to get cured. Let's enjoy the news that Myrcludex trial is also going on and only time will show us which drug is ahead because the final point is to get on the market other than show positive trial results.

[4est]

you destroy the cells with some alcohol ::)) and block the new infection with Mycrludex    - just joking!

Indeed Mycrludex seams to be the best in combination with another drug that will clear some how the infected cells.

[R_2012]

Not sure why either.  Both drugs mentioned above are ahead of Myrcludex.  The GS-9620 results from Phase I/II are due next summer when Myr phase I/II is in December 2013.  I still believe Replicor needs to change their formula away from infusion to have a real chance of marketability.  Based on discussions on this board, Myrcludex has to be used in conjunction with others to clear HBV.  I don't think she disclosed any new information on the interview.